An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib

Background Olaparib is poorly soluble, requiring advanced drug delivery technologies for adequate bioavailability. Sixteen capsules/day are required for the approved 400 mg twice-daily dose; a tablet formulation was developed to reduce pill burden. This clinical trial evaluated the optimal dose and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Targeted oncology 2016-06, Vol.11 (3), p.401-415
Hauptverfasser:	Mateo, J., Moreno, V., Gupta, A., Kaye, S. B., Dean, E., Middleton, M. R., Friedlander, M., Gourley, C., Plummer, R., Rustin, G., Sessa, C., Leunen, K., Ledermann, J., Swaisland, H., Fielding, A., Bannister, W., Nicum, S., Molife, L. R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomedicine Female Humans Male Maximum Tolerated Dose Medicine Medicine & Public Health Oncology Original Research Article Phthalazines - administration & dosage Phthalazines - pharmacology Phthalazines - therapeutic use Piperazines - administration & dosage Piperazines - pharmacology Piperazines - therapeutic use Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage Poly(ADP-ribose) Polymerase Inhibitors - pharmacology Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!